Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Momelotinib + Capecitabine +/- Oxaliplatin in Pancreatic Cancer
NCT02244489Phase 1Terminated
- Sponsor
- GSK
- Start
- Nov 2014
- Primary completion
- Mar 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of momelotinib dihydrochloride in pancreatic ductal adenocarcinoma (PDAC) (2 arms), sponsored by GSK. Primary endpoints: Incidence of dose limiting toxicities up to 21 days and Incidence of adverse events up to 2 years. Started Nov 2014; status: terminated.
02
Drugs
momelotinib dihydrochloride
03
Conditions
pancreatic ductal adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT02244489.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02244489.